KR101912330B1 - 인플루엔자 핵산 분자 및 이로부터 생산된 백신 - Google Patents

인플루엔자 핵산 분자 및 이로부터 생산된 백신 Download PDF

Info

Publication number
KR101912330B1
KR101912330B1 KR1020127022151A KR20127022151A KR101912330B1 KR 101912330 B1 KR101912330 B1 KR 101912330B1 KR 1020127022151 A KR1020127022151 A KR 1020127022151A KR 20127022151 A KR20127022151 A KR 20127022151A KR 101912330 B1 KR101912330 B1 KR 101912330B1
Authority
KR
South Korea
Prior art keywords
influenza
nucleic acid
seq
hemagglutinin
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127022151A
Other languages
English (en)
Korean (ko)
Other versions
KR20130048192A (ko
Inventor
데이비드 비. 와이너
지안 얀
매튜 피. 모로우
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44309124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101912330(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20130048192A publication Critical patent/KR20130048192A/ko
Application granted granted Critical
Publication of KR101912330B1 publication Critical patent/KR101912330B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020127022151A 2010-01-26 2011-01-26 인플루엔자 핵산 분자 및 이로부터 생산된 백신 Expired - Fee Related KR101912330B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/694,238 2010-01-26
US12/694,238 US8298820B2 (en) 2010-01-26 2010-01-26 Influenza nucleic acid molecules and vaccines made therefrom
PCT/US2011/022642 WO2011094358A1 (en) 2010-01-26 2011-01-26 Influenza nucleic acid molecules and vaccines made therefrom

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187030480A Division KR20180118244A (ko) 2010-01-26 2011-01-26 인플루엔자 핵산 분자 및 이로부터 생산된 백신

Publications (2)

Publication Number Publication Date
KR20130048192A KR20130048192A (ko) 2013-05-09
KR101912330B1 true KR101912330B1 (ko) 2018-10-26

Family

ID=44309124

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187030480A Ceased KR20180118244A (ko) 2010-01-26 2011-01-26 인플루엔자 핵산 분자 및 이로부터 생산된 백신
KR1020127022151A Expired - Fee Related KR101912330B1 (ko) 2010-01-26 2011-01-26 인플루엔자 핵산 분자 및 이로부터 생산된 백신

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020187030480A Ceased KR20180118244A (ko) 2010-01-26 2011-01-26 인플루엔자 핵산 분자 및 이로부터 생산된 백신

Country Status (15)

Country Link
US (4) US8298820B2 (enExample)
EP (2) EP3173103A1 (enExample)
JP (2) JP5992337B2 (enExample)
KR (2) KR20180118244A (enExample)
CN (2) CN102753200B (enExample)
AU (1) AU2011209626B2 (enExample)
BR (1) BR112012018587A2 (enExample)
CA (1) CA2786901A1 (enExample)
EA (2) EA031321B1 (enExample)
ES (1) ES2600890T3 (enExample)
HK (1) HK1249139A1 (enExample)
IN (1) IN2012DN06289A (enExample)
MX (3) MX357191B (enExample)
WO (1) WO2011094358A1 (enExample)
ZA (1) ZA201307844B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
BR112012020839A2 (pt) * 2010-02-18 2017-11-21 Sinai School Medicine vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
WO2012036993A1 (en) 2010-09-14 2012-03-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
ES2806263T3 (es) 2011-02-11 2021-02-17 Univ Pennsylvania Molécula de ácido nucleico que codifica la proteína del núcleo del virus de la hepatitis b y vacuna que comprende la misma
RU2612900C2 (ru) 2011-06-20 2017-03-13 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
WO2013019603A2 (en) * 2011-07-29 2013-02-07 Inovio Pharmaceuticals, Inc. Linear expression cassettes and uses thereof
BR112014006694A2 (pt) 2011-09-20 2020-11-17 Mount Sinai School Of Medicine vacinas contra o vírus influenza e usos dessas
RU2653756C2 (ru) * 2012-02-07 2018-05-14 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
EP3305806B1 (en) 2012-02-13 2020-08-26 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
JP2015513902A (ja) 2012-03-30 2015-05-18 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示す、ｈ５ｎ１およびｈ１ｎ１インフルエンザウイルスの抗原
EP2836505B1 (en) * 2012-04-10 2019-01-23 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
KR20150089005A (ko) 2012-11-27 2015-08-04 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 H1n1에 대한 계산적으로 최적화되고 넓은 반응성의 항원
KR20230156146A (ko) * 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
CN104812401B (zh) * 2012-12-13 2017-10-13 宾夕法尼亚大学理事会 Wt1疫苗
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014235556A1 (en) * 2013-03-15 2015-07-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
AU2014240116B2 (en) * 2013-03-15 2016-12-15 The Trustees Of The University Of Pennsylvania Mono or multivalent botulinum neurotoxin based vaccine using the heavy chain from serotypes of Clostridium botulinum
DK2969005T3 (da) 2013-03-15 2020-01-20 The Resaerch Foundation For The State Univ Of New York Attenuerede influenzavira og -vacciner
WO2015023461A2 (en) * 2013-08-06 2015-02-19 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
KR20230093536A (ko) 2013-10-07 2023-06-27 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 어쥬번트로서 인터류킨-33을 갖는 백신
CA2962799A1 (en) 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
EP3226892A4 (en) 2014-12-01 2018-07-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR20170129804A (ko) * 2015-03-20 2017-11-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cd40 리간드를 어쥬번트로서 갖는 백신
EP3402514A4 (en) * 2016-01-15 2019-06-26 Etubics Corporation METHOD AND COMPOSITIONS FOR INFLUENZA VACCINATION
CN117887735A (zh) 2016-05-05 2024-04-16 宾夕法尼亚大学理事会 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法
CN105999257A (zh) * 2016-05-11 2016-10-12 长春海基亚生物技术股份有限公司 无针注射流感疫苗系统与应用
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
CN111511397A (zh) 2017-12-22 2020-08-07 科达金尼克斯有限公司 具有密码子对去优化区域的重组病毒及其用于治疗癌症的用途
CN112040977A (zh) 2018-03-08 2020-12-04 科达金尼克斯有限公司 减毒黄病毒
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN113423421A (zh) * 2018-09-21 2021-09-21 内布拉斯加大学董事会 制备和使用通用中心化流感疫苗基因的方法
CN111514287A (zh) * 2020-04-29 2020-08-11 河南大学 甲型流感通用型dna疫苗及其制备方法和应用
KR102818854B1 (ko) * 2021-07-29 2025-06-13 주식회사 에스엠엘바이오팜 발현 시스템 및 이를 이용한 핵산 기반 백신
CN114854777B (zh) * 2022-04-15 2024-06-25 中山大学 一种基于优化na序列的广谱流感疫苗及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299151A1 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
WO2009073330A2 (en) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
CH682669A5 (fr) 1989-03-08 1993-10-29 Health Research Inc Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
JP3004049B2 (ja) 1989-03-31 2000-01-31 ワシントン ユニバーシティー 病原性のないｐｈｏＰ型微生物を含有するワクチン
DE69016956T2 (de) 1989-12-04 1995-07-20 Akzo Nobel Nv Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
EP0708659A4 (en) 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDE
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
AU2002211490A1 (en) 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
TWI303275B (en) 2003-05-30 2008-11-21 Advisys Inc Devices and methods for biomaterial production
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP4980896B2 (ja) 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
US7568458B2 (en) 2005-01-18 2009-08-04 Borgwarner Inc. Valve event reduction through operation of a fast-acting camshaft phaser
US7566454B2 (en) * 2005-02-24 2009-07-28 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2007100584A2 (en) 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
US20070286873A1 (en) 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
CN101679475B (zh) 2006-07-28 2015-08-12 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
US9452285B2 (en) 2006-10-17 2016-09-27 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
WO2008087563A2 (en) 2006-12-29 2008-07-24 Institut Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use
WO2008124331A1 (en) 2007-04-03 2008-10-16 Cytogenix, Inc. Novel sequences and dna vaccines against avian flu
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
BRPI0815662A2 (pt) * 2007-08-20 2016-09-27 Fraunhofer Usa Inc vacinas, antígenos, composições, e métodos profilácticos e terapêuticos para gripe
HUE030520T2 (en) * 2008-11-28 2017-05-29 Statens Seruminstitut Optimized influenza vaccines
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
CA2788902C (en) 2010-02-08 2019-09-03 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299151A1 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
WO2009073330A2 (en) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus

Also Published As

Publication number Publication date
EP3173103A1 (en) 2017-05-31
US20130052222A1 (en) 2013-02-28
ES2600890T3 (es) 2017-02-13
US20120064116A9 (en) 2012-03-15
WO2011094358A1 (en) 2011-08-04
MX357191B (es) 2018-06-29
JP2013517800A (ja) 2013-05-20
EA201891712A2 (ru) 2019-01-31
HK1249139A1 (zh) 2018-10-26
CN102753200A (zh) 2012-10-24
KR20130048192A (ko) 2013-05-09
JP5992337B2 (ja) 2016-09-14
EA201891712A3 (ru) 2019-05-31
US9192660B2 (en) 2015-11-24
AU2011209626B2 (en) 2013-05-23
US20160030548A1 (en) 2016-02-04
US20180133307A1 (en) 2018-05-17
AU2011209626A1 (en) 2012-08-09
KR20180118244A (ko) 2018-10-30
ZA201307844B (en) 2015-12-23
EP2528626A1 (en) 2012-12-05
JP2016105728A (ja) 2016-06-16
WO2011094358A9 (en) 2012-01-05
EP2528626B1 (en) 2016-09-28
MX2018008135A (es) 2021-11-16
CN102753200B (zh) 2017-11-21
EA031321B1 (ru) 2018-12-28
US8298820B2 (en) 2012-10-30
IN2012DN06289A (enExample) 2015-09-25
BR112012018587A2 (pt) 2020-09-01
EP2528626A4 (en) 2013-07-17
US10363302B2 (en) 2019-07-30
CA2786901A1 (en) 2011-08-04
CN107739736A (zh) 2018-02-27
US20110182938A1 (en) 2011-07-28
MX2012008651A (es) 2012-08-23
EA201201025A1 (ru) 2013-01-30
US9884106B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
KR101912330B1 (ko) 인플루엔자 핵산 분자 및 이로부터 생산된 백신
KR20150127586A (ko) 인플루엔자 핵산 분자 및 이로부터 제조된 백신
CN101877965B (zh) 针对流感病毒的多种亚型的疫苗
US11479605B2 (en) Homodimeric protein constructs
KR102131276B1 (ko) 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
US20240226291A9 (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
EP4251744A1 (en) Virus-like particles and methods of production thereof
US20220047695A1 (en) Compositions comprising self-assembling vaccines and methods of using the same
JP2014534807A (ja) クロスプレゼンテーションを行う樹状細胞を標的としたワクチボディ
JP2019521702A (ja) インフルエンザウイルスを標的とするｄｎａモノクローナル抗体
CN114573716A (zh) 一种含ccl1的融合蛋白、制备方法及应用
CN103333900A (zh) 一种用于弓形虫感染预防的基因及其应用
HK1149176B (en) Vaccines against multiple subtypes of influenza virus
ES2706058T3 (es) Constructos de proteínas homodiméricas
HK40014682B (zh) 新的对抗寨卡病毒的疫苗和用於对抗寨卡病毒的dna抗体构建体的组合
BR112012032922B1 (pt) Proteína homodimérica, molécula de ácido nucleico, composição farmacêutica, método para a preparação de uma proteína homodimérica, e, vacina
HK1189598B (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211023

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211023